Literature DB >> 10693873

Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis.

I Lundberg1, A K Kratz, H Alexanderson, M Patarroyo.   

Abstract

OBJECTIVE: To study the effects of immunosuppressive therapy, in particular, corticosteroids, on morphologic signs of inflammation and expression of cytokines, adhesion molecules, and class I major histocompatibility complex (MHC) antigen in muscle tissue from patients with polymyositis (PM) and dermatomyositis (DM) and to correlate the molecular changes with changes in muscle function.
METHODS: Seven patients with PM and 4 patients with DM underwent muscle biopsy before and after 3-6 months of therapy. Ten of the 11 patients were initially treated with prednisolone 30-60 mg/day. The phenotypes of infiltrating inflammatory cells and the expression of interleukin-1alpha (IL-1alpha) and IL-1beta, adhesion molecules, and class I MHC antigen were studied by immunochemistry. Computerized image analysis was used for quantitation of staining. Muscle function was assessed with a muscle function index score.
RESULTS: Pronounced improvement of muscle function during the treatment period was noted in 8 of the 11 patients. The changes in muscle function coincided with an almost complete disappearance of inflammatory cells, including CD3+ T cells, in the patients with clinical improvement. These patients also exhibited decreased expression of IL-1alpha, IL-1beta, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), leukocyte function-associated antigen 1alpha, and very late activation antigen 4alpha. Of note, there was persistent expression of IL-1alpha, ICAM-1, and VCAM-1 in capillaries and of class I MHC antigens on muscle fibers in several of the patients who, after corticosteroid treatment, still had muscle weakness despite the disappearance of inflammatory infiltrates.
CONCLUSION: Changes in the muscle expression of key molecules in the inflammatory process, such as IL-1alpha and IL-1beta, ICAM-1 and class I MHC antigens, showed a consistent but not complete concordance with changes in and status of muscle function in patients with myositis who received the current standard treatment for the disease. These data indicate that it is possible to further evaluate various therapies for myositis using molecular analysis of muscle biopsy specimens obtained on repeated occasions. In addition, the data demonstrate a dissociation between muscle function and degree of inflammatory infiltration in the affected muscles and suggest that the functional defects are more related to the expression of molecules such as IL-1alpha in muscle capillaries than to the mere presence of inflammatory cells in the affected muscles.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10693873     DOI: 10.1002/1529-0131(200002)43:2<336::AID-ANR13>3.0.CO;2-V

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  35 in total

Review 1.  Neutrophilic dermatoses and autoinflammatory diseases with skin involvement--innate immune disorders.

Authors:  Alexander A Navarini; Takashi K Satoh; Lars E French
Journal:  Semin Immunopathol       Date:  2015-11-30       Impact factor: 9.623

2.  Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.

Authors:  Sevim Barbasso Helmers; Maryam Dastmalchi; Helene Alexanderson; Inger Nennesmo; Mona Esbjörnsson; Björn Lindvall; Ingrid E Lundberg
Journal:  Ann Rheum Dis       Date:  2007-02-02       Impact factor: 19.103

3.  The inflammatory milieu in idiopathic inflammatory myositis.

Authors:  Ann M Reed; Floranne Ernste
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

4.  The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy.

Authors:  William Coley; Sree Rayavarapu; Gouri S Pandey; Richard L Sabina; Jack H Van der Meulen; Beryl Ampong; Robert L Wortmann; Rashmi Rawat; Kanneboyina Nagaraju
Journal:  Arthritis Rheum       Date:  2012-11

Review 5.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

6.  Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis.

Authors:  C Dorph; P Englund; I Nennesmo; I E Lundberg
Journal:  Ann Rheum Dis       Date:  2006-07-10       Impact factor: 19.103

7.  High- density lipoprotein function is abnormal in idiopathic inflammatory myopathies.

Authors:  Sangmae Sharon Bae; Yuen Yin Lee; Ani Shahbazian; Jennifer Wang; David Meriwether; Ilana Golub; Buzand Oganesian; Tyler Dowd; Srinivasa T Reddy; Christina Charles-Schoeman
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.580

Review 8.  The skeletal muscle arachidonic acid cascade in health and inflammatory disease.

Authors:  Marina Korotkova; Ingrid E Lundberg
Journal:  Nat Rev Rheumatol       Date:  2014-01-28       Impact factor: 20.543

Review 9.  Corticosteroids in Myositis and Scleroderma.

Authors:  Anna Postolova; Jennifer K Chen; Lorinda Chung
Journal:  Rheum Dis Clin North Am       Date:  2015-10-26       Impact factor: 2.670

10.  Safety and efficacy of ultrasound-guided intra-articular hylan G-F 20 injection in osteoarthritis of the hip: a pilot study.

Authors:  Hanife Caglar-Yagci; Sibel Unsal; Ilker Yagci; Deniz Dulgeroglu; Sumru Ozel
Journal:  Rheumatol Int       Date:  2004-03-05       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.